Welcome To Poole
Related Articles
[ad_1]
OOn Monday, two large pharmaceutical companies delivered good news on one of their projects. Merck (NYSE: MRK) and AstraZeneca (NASDAQ: (AZN)) announced in separate press releases that their anti-cancer drug Lynparza has received approval from the Japanese pharmaceutical regulator for the treatment of three types of diseases: prostate, ovaries and pancreas.
The country’s Ministry of Health, Labor and Welfare has approved Lynparza as a maintenance treatment after first-line chemotherapy has been given to patients with certain types of these cancers.
Image source: Getty Images.
“For patients in Japan diagnosed with each of these types of cancer, there are very few treatment options,” the companies said, citing Merck Research Laboratories head of global clinical development, Roy Baynes.
“Approvals for treatments such as Lynparza, the first PARP inhibitor to be approved in these specific types of metastatic castration-resistant prostate cancer and metastatic pancreatic cancer in Japan, allow us to advance this evolving era. personalized medicine and changing the way these cancers are treated, “he added.
According to the two companies, this year nearly 11,000 women in Japan were diagnosed with ovarian cancer. During 2020, more than 5,000 died from it. At the same time, there were over 100,000 new cases of prostate cancer in the country during the year and around 44,000 new cases of pancreatic cancer.
This is the last green light for Merck and AstraZenecaof the drug, which received its first major approvals in 2014 from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) of the European Union.
Both stocks closed higher on the news, although Merck’s 0.4% gain lagged the 0.9% rise in S&P 500 index. AstraZeneca shares rose 1.8% on the day.
10 stocks we like better than Merck & Co.
When investment geniuses David and Tom Gardner have stock advice, he can pay to listen. After all, the newsletter they’ve been distributing for over a decade, Fintech Zoom Stock Advisor, has tripled the market. *
David and Tom just revealed what they think are the ten best stocks investors can buy right now… and Merck & Co. was not one of them! That’s right – they think these 10 stocks are even better buys.
See the 10 actions
* Stock Advisor returns as of November 20, 2020
Eric Volkman does not have a position in any of the stocks mentioned. Fintech Zoom has no position in any of the stocks mentioned. Fintech Zoom has a disclosure policy.
The views and opinions expressed here are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
